Omeros Co. (OMER) Earns Outperform Rating from Cowen and Company
Omeros Co. (NASDAQ:OMER)‘s stock had its “outperform” rating restated by equities research analysts at Cowen and Company in a research note issued on Monday.
Several other brokerages also recently weighed in on OMER. Maxim Group reiterated a “buy” rating and set a $22.00 target price (up previously from $19.00) on shares of Omeros in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price (down previously from $24.00) on shares of Omeros in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 target price on shares of Omeros in a research note on Friday. FBR & Co reiterated a “buy” rating on shares of Omeros in a research note on Thursday, March 2nd. Finally, Zacks Investment Research upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research note on Tuesday, November 22nd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $33.38.
Shares of Omeros (NASDAQ:OMER) traded up 11.48% during trading on Monday, hitting $11.75. The company had a trading volume of 1,195,313 shares. The firm’s market capitalization is $504.25 million. Omeros has a 52-week low of $7.20 and a 52-week high of $16.38. The stock’s 50-day moving average is $11.05 and its 200 day moving average is $10.51.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/omeros-co-omer-earns-outperform-rating-from-cowen-and-company.html
Your IP Address:
Several large investors have recently made changes to their positions in OMER. Ingalls & Snyder LLC increased its stake in shares of Omeros by 15.2% in the third quarter. Ingalls & Snyder LLC now owns 5,085,949 shares of the biopharmaceutical company’s stock valued at $56,759,000 after buying an additional 671,370 shares during the period. Bank of Montreal Can increased its stake in shares of Omeros by 20.2% in the third quarter. Bank of Montreal Can now owns 2,015,248 shares of the biopharmaceutical company’s stock worth $22,490,000 after buying an additional 338,263 shares during the last quarter. Cpcm LLC purchased a new stake in shares of Omeros during the fourth quarter worth approximately $12,709,000. Tocqueville Asset Management L.P. increased its stake in shares of Omeros by 0.4% in the third quarter. Tocqueville Asset Management L.P. now owns 959,744 shares of the biopharmaceutical company’s stock worth $10,711,000 after buying an additional 3,741 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Omeros by 4.6% in the fourth quarter. State Street Corp now owns 943,121 shares of the biopharmaceutical company’s stock worth $9,362,000 after buying an additional 41,284 shares during the last quarter. Institutional investors and hedge funds own 47.94% of the company’s stock.
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Ratings for Omeros Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Co. and related companies with MarketBeat.com's FREE daily email newsletter.